Service interruption on Monday 11 July from 12:30 to 13:00: all the sites of the CCSD (HAL, Epiciences, SciencesConf, AureHAL) will be inaccessible (network hardware connection).
Skip to Main content Skip to Navigation
Journal articles

The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment

Abstract : INTRODUCTION: In Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), the BCR-ABL translocation is the main transforming event; consequently, it is targeted by ABL-tyrosine kinase inhibitors (TKIs), the first of which to be identified was imatinib mesylate. There are now four newer TKIs, three so-called second-generation inhibitors and one third generation inhibitor, all of which are more potent than imatinib in in vitro assays. Areas covered: This paper reviews the current knowledge on the function of BCR-ABL. Furthermore, this paper highlights the impact of this knowledge on the development of a targeted therapy approach in Ph+ ALL and the obstacles for the successful treatment with these drugs. Expert opinion: Identifying key components involved in disease pathogenesis may lead to new approaches that might overcome resistance mediated to the BCR-ABL TKIs. In a near future, the authors believe that monoclonal antibodies and immunotherapy should also be combined with TKIs and up-front chemotherapy for the successful treatment of ALL
Document type :
Journal articles
Complete list of metadata

https://hal-univ-lyon1.archives-ouvertes.fr/hal-01796194
Contributor : Lauriane Pillet Connect in order to contact the contributor
Submitted on : Saturday, May 19, 2018 - 11:34:26 AM
Last modification on : Wednesday, November 3, 2021 - 4:35:04 AM

Identifiers

Collections

Citation

Xavier Thomas, Maël Heiblig. The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment. Expert Opinion on Drug Discovery, Informa Healthcare, 2016, 11 (11), pp.1061-1070. ⟨10.1080/17460441.2016.1227318⟩. ⟨hal-01796194⟩

Share

Metrics

Record views

22